Key Highlights

  • Pfizer (NYSE:PFE) struck a deal on November 11, 2026 for funds run by Blackstone Life Sciences to cover as much as USD 1.5 billion of costs for its once-monthly obesity candidate.
  • Amgen's dazodalibep lowered Sjogren's disease activity scores by 5.6 points versus 3.8 for placebo at week 48, and a second Phase 3 study is expected to finish this quarter.
  • Johnson & Johnson's Caplyta hit its targets in a second Phase 3 bipolar mania study, with 43.9% of patients responding against 23.7% on placebo.
  • Each drugmaker is leaning on new products as older franchises face Patent cliffs and tougher pricing.

1. Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) revealed a financing arrangement after markets closed on November 11. Funds managed by Blackstone Life Sciences will cover up to USD 1.5 billion of development spending through 2028 on berobenatide, a GLP-1 injection given once a month and now in Phase 3 for obesity. The backer takes no stake and no rights to the medicine. Its return is a series of milestone payments, owed over several years only if the product is approved in the US as a standalone monthly shot and hits agreed sales thresholds. Should the programme fail, Pfizer keeps the money. Obesity studies enrol thousands of people and run for a long time, so shifting part of that bill to outside Capital lightens the load in the most expensive stage. The company has more than 20 obesity and related trials planned for 2026, among them 10 ongoing or planned Phase 3 studies of berobenatide. A monthly schedule would stand apart from the weekly products that lead the market and could attract people who dislike frequent injections. Still, the arrangement leaves scientific risk untouched, and milestone payouts would trim profit if the drug works. As rivals multiply, obesity pricing is under growing strain. The stock has trailed healthcare peers, which makes a clean first Phase 3 readout the key trigger to watch.

2. Amgen (NASDAQ:AMGN)

On November 11, Amgen (NASDAQ:AMGN) shared full late-stage data for dazodalibep in Sjogren's disease. After 48 weeks, disease activity scores dropped 5.6 points on 1,500 mg given every four weeks and 5.2 points on 3,000 mg given every 12 weeks, compared with 3.8 points for placebo, and each comparison reached statistical significance. Patients on the monthly schedule also reported meaningfully less dryness, an important detail because earlier experimental drugs tended to shift doctor-rated measures without improving how people felt day to day. Side effect rates looked alike across all arms. Sjogren's is a long-term autoimmune illness in which the body attacks glands that make tears and saliva. Millions live with it, but care has mostly addressed symptoms and not the underlying course. The drug blocks CD40 ligand, a signal that lets T cells switch on B cells, and arrived through the Horizon Therapeutics purchase. If it proves disease-modifying and offers a dosing option every quarter, it could grow into a major product. For context, the latest Quarterly Report showed Revenue of USD 10.4 billion, up 8%, and full-year guidance of USD 38.9 billion to USD 39.7 billion. Rival drugmakers are pursuing competing mechanisms, and the strong placebo response underlines how tough this disease is to study. The second Phase 3 trial, OASIZ 303, is due to complete this quarter.

3. Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) reported on November 10 that Study 452, its second Phase 3 trial of Caplyta in adults with manic episodes of bipolar I disorder, achieved both the primary and key secondary endpoints. A once-daily 42 mg dose beat placebo by 3.7 points on the Young Mania Rating Scale at week three, with an effect visible from day three, and the response rate was 43.9% versus 23.7%. Because Study 451 was also positive, the company holds the pair of pivotal studies usually required and intends to file in the US, with a ruling most likely in 2027. Caplyta came over with the 2025 Intra-Cellular Therapies deal and is already cleared for bipolar depression, major depressive disorder and schizophrenia. A mania claim would span both ends of bipolar I, which psychiatrists who want a single treatment for their patients will value. Modest weight gain and few movement-related side effects also help people stay on therapy. Neuroscience ranks among the quickest-growing areas of the company's pharmaceutical unit and helps cushion biosimilar erosion in older immunology products. One new indication barely moves group sales, and generic antipsychotics crowd the acute mania space. Even so, this is the most predictable path to approval among the three stories.

Where Things Stand

Amgen's news carries the most weight among the top 3 big pharma pipeline updates of the week. Dazodalibep may anchor a fresh immunology Franchise in a sizeable disease that lacks any disease-modifying treatment, and a second Phase 3 result is only weeks away. Pfizer's financing trims the expense of its obesity push but leaves the science risk in place, while Johnson & Johnson's Caplyta success is the surest bet yet the smallest financially. Canadian investors should watch for OASIZ 303 results and the first berobenatide Phase 3 data next.